September 15, 2025

The Hidden Hazard: Fall-Risk Drugs

US fall-related deaths in older adults are rising, with prescription drugs a key contributor and safer alternatives urged.

KFF Health News

September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

September 10, 2025

Medical Societies Challenge Kennedy

"That you can no longer trust the recommendations out of the CDC is just devastating."

Conexiant

September 09, 2025

Merger Cure? Rural Hospitals Try Networks

Mobile magnetic resonance imaging units and rural hospital networks support independent hospitals in improving access to diagnostic imaging and patient care in underserved areas.

KFF Health News

September 08, 2025

FDA Expands Indications for Von Willebrand Disease

FDA expands Vonvendi to adult routine prophylaxis (types 1 and 2) and pediatric on-demand/perioperative use.

Conexiant

September 04, 2025

'No Standard of Care' for GLP-1 Weaning

Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates

KFF Health News

September 04, 2025

AI Tool Detects Lupus From Eye Scans

DeepSLE uses retinal images to identify systemic lupus erythematosus and related complications with high accuracy across diverse populations, outperforming physicians in a prospective comparison.

Conexiant

September 03, 2025

FDA Approves Denosumab Biosimilars

The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.

Conexiant

September 02, 2025

New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response

The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.

Conexiant